RESEARCH
CATALOG

Slow-release methylated B-vitamin complex modeled on the Igennus Super B-Complex formulation. All eight B vitamins delivered in their active or bioidentical forms - folate as L-5-MTHF (not folic acid), B12 as methylcobalamin (not cyanocobalamin), B6 as pyridoxal-5-phosphate. Sustained-release matrix extends absorption over 4-6 hours. 60 tablets per bottle. Pharmacy-grade purity, USP/EP-compliant raw materials.

First-generation antihistamine with combined H1 receptor and 5-HT2 serotonin receptor antagonism. Used in research on MCAS-related histamine signaling, appetite-stimulant pathways, migraine prophylaxis mechanisms, and serotonin-syndrome reversal. 4 mg per tablet, 50 tablets per bottle. Pharmacy-grade purity.

Sustained-release combination of T3 (liothyronine) and 3,5-T2 (3,5-diiodo-L-thyronine) at 45 mcg each in a 1:1 ratio per capsule. HPMC slow-release matrix extends release over 4-8 hours. Used in research on T3-protocol plateau correction, mitochondrial co-activation, and the T3->T2 conversion bottleneck.

Sustained-release combination of T3 (liothyronine) and 3,5-T2 (3,5-diiodo-L-thyronine) at 7.5 mcg each in a 1:1 ratio per capsule. HPMC slow-release matrix extends release over 4-8 hours. Used in research on T3-protocol plateau correction, mitochondrial co-activation, and the T3->T2 conversion bottleneck.

Sustained-release combination of T3 (liothyronine) and 3,5-T2 (3,5-diiodo-L-thyronine) at 15 mcg each in a 1:1 ratio per capsule. HPMC slow-release matrix extends release over 4-8 hours. Used in research on T3-protocol plateau correction, mitochondrial co-activation, and the T3->T2 conversion bottleneck.

Sustained-release combination of T3 (liothyronine) and 3,5-T2 (3,5-diiodo-L-thyronine) at 22.5 mcg each in a 1:1 ratio per capsule. HPMC slow-release matrix extends release over 4-8 hours. Used in research on T3-protocol plateau correction, mitochondrial co-activation, and the T3->T2 conversion bottleneck.

The complete Wilson's Temperature Syndrome T3+T2 protocol kit. Includes 1x SRT3+T2-7.5, 1x SRT3+T2-15, 1x SRT3+T2-22.5, and 1x SRT3+T2-45. Each capsule contains T3 and 3,5-T2 in a 1:1 mcg ratio. Designed for cyclic titration protocols that address both the T4->T3 conversion problem (via the T3 component) and the often-overlooked T3->T2 conversion problem (via the T2 component).

Sustained-release combination of T3 (liothyronine) and 3,5-T2 (3,5-diiodo-L-thyronine) at 90 mcg each in a 1:1 ratio per capsule. HPMC slow-release matrix extends release over 4-8 hours. Used in research on T3-protocol plateau correction, mitochondrial co-activation, and the T3->T2 conversion bottleneck.